AIDD overview

The Alpine Institute for Drug Discovery will perform translational discovery on previously intractable or novel therapeutic targets using tailored combinations of cutting-edge technologies. 

AIDD will focus on immunotherapeutics for oncology, autoimmune and inflammatory diseases. Through open innovation collaborations with academia and industry, AIDD will become a partner of choice for translational discovery and a stable, trusted provider of high-quality lead compounds for pharmaceutical partners and venture investors. 

AIDD will meet the rapidly growing need for innovative drug discovery and become sustainable by licensing lead compounds to pharmaceutical companies or venture investors looking to create asset-centric startup companies. 

The AIDD team has a strong track record in translating novel biology into small molecule or antibody pre-medicines, and in managing and leveraging the related intellectual property. With its  expertise in allosteric modulator discovery and development, AIDD will combine its own ultra sensitive cellular Aura Assays for high throughput screening with a number of highly sophisticated and mutually reinforcing technologies from partners: systems for antibody-enabled drug discovery (AEDD); fragment-based drug discovery (FBDD); structure-based drug design (SBDD); and native membrane protein extraction (NMPE).

Specifically tailored for each therapeutic target of interest, combinations of these approaches address two of the key bottlenecks in drug discovery: 1) previously intractable therapeutic targets will become amenable to drug discovery; 2) medicinal chemistry will be informed by both functional and structural data, maximizing chance of success. As a result, projects will advance more rapidly or get terminated faster. Simply put, AIDD’s multidisciplinary approach will facilitate more efficient data-driven progression towards clinical candidate selection.

AIDD is fostering relationships with leading research institutions throughout the world to scout for novel targets, disease models, expertise and complementary enabling technologies, and to assist partners with target identification and validation efforts. 

AIDD’s ambition is to become a new source of innovation in today’s vertically disintegrating pharmaceutical landscape.